​The head of SHINE Technologies’ therapeutics division says the company is moving from research and development into the commercial stage for a precision cancer treatment product.

The Janesville company recently submitted its “drug master file” to the FDA, which includes information on facilities, procedures and other details for production of non-carrier-added lutetium-177 chloride. This radiopharmaceutical product is paired with “cancer-seeking” molecules to target and damage or destroy cancer cells, Chris Vessell explained in an interview yesterday.

To read more please visit:

SHINE moving from R&D into the commercial stage for cancer therapy product, exec says